US 12,109,260 B2
Zika vaccines and immunogenic compositions, and methods of using the same
Jill A Livengood, Cambridge, MA (US); Hansi Dean, Cambridge, MA (US); Htay Htay Han, Cambridge, MA (US); Raman Rao, Singapore (SG); Jackie Marks, Cambridge, MA (US); Gary Dubin, Zurich (CH); Laurence De Moerlooze, Zurich (CH); Hetal Patel, Cambridge, MA (US); and Sushma Kommareddy, Cambridge, MA (US)
Assigned to Takeda Vaccines, Inc., Cambridge, MA (US)
Filed by TAKEDA VACCINES, INC., Cambridge, MA (US)
Filed on Jun. 16, 2023, as Appl. No. 18/336,439.
Application 18/336,439 is a continuation of application No. 16/761,329, granted, now 11,730,802, previously published as PCT/US2018/059233, filed on Nov. 5, 2018.
Claims priority of provisional application 62/592,995, filed on Nov. 30, 2017.
Claims priority of provisional application 62/581,500, filed on Nov. 3, 2017.
Prior Publication US 2023/0414743 A1, Dec. 28, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24034 (2013.01); C12N 2770/24071 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); C12N 2770/24164 (2013.01)] 30 Claims
 
1. A method of vaccinating against Zika virus infection in a human subject in need thereof, the method comprising administering to the human subject a vaccine or immunogenic composition comprising an antigen from a Zika virus, wherein the vaccine or immunogenic composition is administered as a multi dose administration comprising a first (prime) and a second (boost) administration and wherein administration of the vaccine or immunogenic composition induces 14 and/or 28 days after the boost administration a seroconversion rate of at least 80%, at least 90%, at least 95%, or 100% in a human subject population of at least 20 flavivirus naïve human subjects or at least 20 Zika virus seronegative human subjects.